Revolution Medicines’ newly launched treatment recorded sales far above expectations in its first few weeks on the market.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on MarketWatch ↗
Keywords
pharmaceuticalshealthcarecancerRevolution Medicines
Open a keyword to see other news on the same topic.
Related news
- Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Duquesne Family Office, led by billionaire Stanley Druckenmiller, increased its Revolution Medicines stake by 26.5% in the second quarter, before the company's Rasonque won U.S. approval in August for certain pancreatic cancer patients. In a Phase 3 study, Rasonque achieved median overall survival of 13.2 months versus 6.7 months for chemotherapy, and some estimates project it could generate $15.1 billion in revenue by 2034 from pancreatic cancer alone. Some estimates put the number of U.S. patients diagnosed annually with metastatic pancreatic cancer at 55,000, with about 19,000 moving on to second-line treatment; assuming a roughly 30% net discount, the opportunity is nearly $3 billion a year. With a market cap of about $40 billion that has fallen since approval, the author says that at a 12% required rate of return and a forward price-to-sales ratio of 4 by 2031, revenue would need to reach $17.62 billion in 2032 to justify the current valuation. The author says they would seriously consider investing if the market cap falls by another $5 billion, citing clinical, regulatory and biotech volatility risks.
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer
Reed Jobs, founder of oncology-focused venture capital firm Yosemite and son of Steve Jobs, told Fortune that GLP-1 drugs could be among the most important medicines to reach the market, with possible implications for cancer and cardiovascular disease. He called the GLP-1 revolution one of the biggest biotechnology developments of the past three years, while acknowledging drawbacks such as muscle loss. A JAMA Oncology study of 86,632 adults found GLP-1 users had a 17% lower hazard of developing the 14 cancers studied than nonusers, though the finding shows an association rather than proof that the drugs prevent cancer directly. Jobs said Yosemite's second fund exceeded its $350 million target and was oversubscribed, with AbbVie and Amgen among the investors. A Deloitte report found obesity drugs accounted for 25% of late-stage pipeline sales forecasts for major pharmaceutical companies, up from 1% in 2022.
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi cut the risk of death by 58% in patients with extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months, compared with 12.7 months for Imfinzi alone, in patients whose cancer had not progressed after initial Imfinzi and chemotherapy. Nearly 80% of patients on the combination were alive at one year, versus 53% on Imfinzi alone. Imdelltra posted $288 million in second-quarter sales, up 115% year over year, after $627 million in global sales in 2025. Amgen said the results suggest earlier use of the drug could meaningfully alter the course of the disease, though the trial did not compare the combination with other first-line treatments.
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
The first Phase 3 data for a cancer vaccine has raised doubts about whether the potential treatment is needed. According to the headline, the real test lies in keeping cancer from returning over the long term rather than in beating Keytruda.
- Could Revolution Medicines Be a Millionaire-Maker Stock?
Revolution Medicines (RVMD) shares have risen more than 130% following FDA approval in August 2026 of its pancreatic cancer drug Rasonque (daraxonrasib). To turn a $25,000 investment into $1 million, the company would need a market cap of roughly $1.6 trillion, compared with about $1.2 trillion for Eli Lilly. RBC Capital Markets estimates Rasonque's peak annual sales at $11.5 billion, which at the biotech industry's average price-to-sales ratio of 8.4 would imply a market cap near $97 billion. The article says the stock is probably unlikely to reach $1.6 trillion, but it could still deliver market-beating returns for long-term investors if pipeline candidates zoldonrasib and elironrasib win approvals. Billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake by 26.5% in the third quarter of 2026.
- These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
The article compares two lesser-known stocks, Revolution Medicines (RVMD) and Oruka Therapeutics (ORKA), which have both more than doubled this year and outpaced the Magnificent Seven. Revolution Medicines earned approval this year for Rasonque in metastatic pancreatic cancer, with a Phase 3 median overall survival of 13.2 months versus 6.7 months for cytotoxic chemotherapy, and some analysts project $20.8 billion in total peak revenue. Its average price target of $259.14 implies 35.7% upside, which the author considers too optimistic. Oruka has no approved medicine; its lead candidate ORKA-001, for plaque psoriasis, is in Phase 2a with encouraging results and could be dosed once or twice a year, while its $155 average target implies 95% upside. The author views Oruka as riskier than Revolution Medicines because ORKA-001 has not yet started Phase 3 trials.
Related markets
Latest news
- What Axcelis Technologies (ACLS) Said on Its Q3 Earnings Call
Axcelis reported third-quarter revenue of $238 million and diluted EPS of $1.26, beating expectations as demand improved across several semiconductor equipment markets. Bookings reached $222 million, the highest quarterly level since the fourth quarter of 2023, while backlog rose to $531 million and CS&I revenue hit a record $93 million; the system book-to-bill ratio was 1.5. For the fourth quarter, the company forecasts revenue of about $275 million and EPS of about $1.50, and expects first-quarter 2027 revenue to be roughly level with that. Management sees a broadening recovery and expects growth in memory, power and mature applications in 2027. The pending Veeco merger is now expected to close by the end of the first quarter of 2027, subject to China regulatory clearance, and a $35 million Korean facility is set to begin production in the second half of 2028.
- What Deutsche Telekom (DTE) Said on Its Q3 Earnings Call
Deutsche Telekom raised its 2026 outlook to about EUR 47.6 billion in adjusted EBITDA and EUR 20.1 billion in free cash flow, citing higher guidance from T-Mobile US. Third-quarter organic service revenue rose 4% and adjusted EBITDA grew 8%, while broadband additions in Germany turned positive and fiber customer additions reached 190,000, up 23% year over year. The company proposed a EUR 1.10 dividend for 2026 and up to EUR 2 billion in share buybacks for 2027, bringing total shareholder returns to about EUR 7 billion. Management said satellite services are not expected to replace terrestrial networks and reaffirmed its German fiber strategy, though higher costs for network components continue to weigh on the business.
- Amazon Teams Up With Uber Eats, Sending DoorDash Stock Tumbling
DoorDash shares fell after Amazon launched a partnership with Uber to offer restaurant delivery to Prime members.
- Why Micron Stock Keeps Going Down
Micron shares have fallen nearly 30% over the last six trading days, though they remain up more than threefold over 52 weeks, and Sandisk fell another 13% in the same session. Many investors blame China's CXMT, which is developing a new “4F square” memory chip to market as HBM and reports $1 billion in customer prepayments for its DRAM chips, a 15.7-fold increase from the end of 2025, according to DigiTimes. The article notes Micron is the world's third-largest DRAM supplier and CXMT is fourth, but CXMT lags far behind in HBM, where SK Hynix holds at least a 50% share and CXMT's next-generation HBM3E yields are only 20% to 30%.
- SPY support levels: three key floors to watch
SPY is trading at $746.84, down 2.60%, as of 10:38 AM EST on Nov 5, 2026, after an intraday low of $744.81. The article identifies three support zones: $744.80–$746.30 (immediate), $736.80–$741.50 (secondary), and $729.10–$730.22 (major, including the July 29 swing low and the daily 200-day SMA). Daily momentum is bearish, with RSI at 38.82, MACD histogram at -1.86, and a daily gauge reading of Strong Sell, but RSI is not yet below 30, so downside momentum is not deeply oversold. The weekly picture is less damaged, with weekly RSI at 49.41 and the weekly S1 at $746.27 near the current price, a possible but unconfirmed stabilization zone. A break below $744.80 would shift focus to $736.80–$741.50, and a move below $729.10 would damage the longer-term trend.
- Boost Run Announces Date of Third Quarter 2026 Financial Results Conference Call
Boost Run (Nasdaq: BRUN) plans to release its financial results for the third quarter ended September 30, 2026, before market open on Thursday, November 12, 2026. The company will host a conference call at 9:00 a.m. Eastern Time the same day to discuss the results, with a press release and supplemental financials posted on its investor website and an archived replay available for a limited time.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.